← Akebia Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.5m |
$181.2m
+11706.32%
|
$207.7m
+14.63%
|
$335.0m
+61.26%
|
$295.3m
-11.85%
|
$213.6m
-27.68%
|
$292.5m
+36.94%
|
$194.6m
-33.46%
|
$160.2m
-17.70%
|
$236.2m
+47.46%
|
$219.1m
-7.25%
|
|
| Cost of Revenue | $115.8m |
$230.9m
+99.42%
|
$6.3m
-97.29%
|
$108.9m
+1642.68%
|
$295.9m
+171.64%
|
$153.4m
-48.16%
|
$85.6m
-44.22%
|
$74.1m
-13.34%
|
$63.2m
-14.80%
|
$39.5m
-37.54%
|
$44.6m
+13.10%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | $148.9m |
$117.4m
-21.17%
|
$49.5m
-57.80%
|
$38.1m
-23.06%
|
$27.1m
-28.79%
|
$39.5m
+45.43%
|
$44.6m
+13.10%
|
|
| Gross Profit (Calculated) (derived) | ($114.2m) |
($49.7m)
+56.53%
|
$200.0m
+502.64%
|
$189.7m
-5.16%
|
($601k)
-100.32%
|
$60.2m
+10113.98%
|
$206.9m
+243.81%
|
$120.5m
-41.78%
|
$97.0m
-19.48%
|
$196.7m
+102.81%
|
— | |
| Research and Development Expense | $115.8m | $230.9m | $291.0m | $323.0m | $218.5m | $147.9m | $130.0m | $63.1m | $37.7m | $62.4m | $70.5m | |
| General and Administrative Expense | $22.2m | $27.0m | $87.1m | $149.5m | $153.9m | $174.2m | $138.6m | $100.2m | $106.5m | $107.5m | — | |
| Amortization of Intangible Assets | — | — | $1.5m | $36.4m | $31.5m | $36.0m | $36.0m | $36.0m | $36.0m | $0 | — | |
| Operating Expenses | $138.0m | $257.9m | $378.1m | $476.0m | $375.8m | $325.5m | $287.7m | $166.7m | $147.5m | $173.2m | $187.6m | |
| Operating Income (Loss) | ($136.5m) |
($76.7m)
+43.81%
|
($178.2m)
-132.36%
|
($286.3m)
-60.69%
|
($376.4m)
-31.49%
|
($265.3m)
+29.52%
|
($80.8m)
+69.55%
|
($46.3m)
+42.74%
|
($50.5m)
-9.11%
|
$23.5m
+146.56%
|
($13.2m)
-156.09%
|
|
| Other Nonoperating Income (Expense) | ($188k) | $204k | $81k | ($794k) | $1.9m | $2.4m | $3.1m | $887k | $94k | $58k | — | |
| Interest Income (Expense), Nonoperating, Net | — | $2.8m | $6.2m | $792k | ($8.9m) | ($19.9m) | ($15.7m) | ($6.0m) | ($18.2m) | ($24.2m) | $3.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $136.5m | $79.9m | $178.2m | $286.3m | $376.4m | $265.3m | $79.1m | $46.3m | $50.5m | ($3.7m) | ($27.8m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $136.5m | ($73.7m) | ($171.9m) | ($286.3m) | ($383.5m) | ($282.8m) | ($94.2m) | ($51.9m) | ($69.4m) | ($3.7m) | ($27.8m) | |
| Income Tax Expense (Benefit) | $0 | $0 | ($28.3m) | ($6.6m) | $0 | $0 | $0 | $0 | $0 | $1.6m | $1.8m | |
| Net Income (Loss) Attributable to Parent | ($135.7m) |
($73.7m)
+45.73%
|
($143.6m)
-94.90%
|
($279.7m)
-94.76%
|
($383.5m)
-37.12%
|
($282.8m)
+26.24%
|
($94.2m)
+66.69%
|
($51.9m)
+44.89%
|
($69.4m)
-33.67%
|
($5.3m)
+92.30%
|
($29.7m)
-455.02%
|
|
| Earnings Per Share, Basic | — | ($1.77) | ($2.47) | ($2.36) | ($2.77) | ($1.70) | ($0.52) | ($0.28) | ($0.33) | ($0.02) | ($0.12) | |
| Earnings Per Share, Diluted | — | ($1.77) | ($2.47) | ($2.36) | ($2.77) | ($1.70) | ($0.52) | ($0.28) | ($0.33) | ($0.02) | ($0.12) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 165.9m | 182.8m | 187.5m | 210.9m | 257.2m | 266.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 165.9m | 182.8m | 187.5m | 210.9m | 257.2m | 266.8m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | — | — | — | — | — |